Abstract
Perhaps the key trend in 2020 for the cellular immunotherapy field was the emergence and advancement into the clinic of a new wave of novel allogeneic product candidates. Allogeneic approaches offer clear advantages over autologous cell therapies, ranging from a less complex, more ‘pharma-friendly’ supply chain and less variable, healthier manufacturing starting materials, through to reduced wait manufacturing bringing Cost of Goods efficiencies, and potentially lower price points for a healthcare sector under growing financial constraints. However, there are some imposing obstacles to be addressed relating to demonstrating both safety and efficacy in the clinic, as well as overcoming scalability issues. In this month’s Clinical Trends, we dissect the development plans and ongoing clinical studies of some of the key industry players.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
